A postpartum depression study from Lipocine is expected to enroll about 120 people.
Lipocine initiated a Phase 3 study for postpartum depression treatment BRLIZIO™, expecting to enroll 120 participants. The study aims to support a potential NDA submission. The company also reported financial results for Q3 and the first nine months of 2026, showing net losses and revenue. Lipocine is exploring partnerships for BRLIZIO™ and other programs, including LPCN 2201 for MDD and LPCN 2203 for essential tremor.
How this was made
The 30-second read
Why it matters
A Phase 3 start is a key milestone that can move the stock ahead of the trial’s outcomes.
Market read
First‑report of a Phase 3 trial start for a novel postpartum‑depression drug, a material catalyst for LPCN.
What to watch
Funding availability and enrollment speed could limit trial execution.
Background
Lipocine is a NASDAQ‑listed biopharma focused on oral drug‑delivery platforms; the BLOOM study targets a high‑unmet‑need indication.
Ticker impact
Lipocine announced the initiation of the Phase 3 BLOOM study for postpartum depression, planning to enroll about 120 participants.
potential upside as investors price in the positive momentum from a Phase 3 start
Phase 3 initiation is a material catalyst for a biotech; the market typically reacts favorably to progress in a novel indication.
Market effects
May lift sentiment across the biotech sector, especially companies developing mental‑health therapeutics.
Adds positive momentum to the US biotech market.
Highlights growing interest in postpartum‑depression treatments worldwide.
Counterpoint
The trial could encounter safety or efficacy setbacks, which would pressure the stock.
Key entities
- companyLipocine Inc.
Biopharmaceutical company developing oral therapeutics.


